Abstract:Abstract Abstract 4485 Background: The prognosis for patients with chronic myeloid leukemia (CML) in advanced phases remains dismal, especially for those who develop ABL mutation. Administration of second-generation tyrosine kinase inhibitors (TKI) might provide an effective approach for patients with BCL-ABL mutation, but it only offers short-tem benefit in most cases. Allogeneic stem cell transplantation (allo-SCT) seems the only curative therapy for advanced CML, and limited data exist on the effectiveness of allo-SCT following prior treatment with new TKI dasatinib. Objective and Methods: To evaluate the efficacy of this combination therapy, patients with advanced disease harboring BCL-ABL mutation were enrolled between May 2009 and May 2010, and given dasatinib for a predetermined period, and then referred to myeloablative allo-SCT. All the patients were conditioned with busulfan/cyclophosphamide based regimens. ATG was used for those who received HLA-haploidentical transplantation. Cyclosporin, mycophenolate mofetil and short-term methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. Results: (1) Five patients with accelerated phase (n=1) and blast crisis (n=4) were enrolled. The median age was 37 years (range, 11–42 years). All the patients had a history of chronic phase (CP) before enrollment. Three patients progressed to advanced phases on imatinib. The other two patients didn't receive any TKIs during the CP. When progressing to blast crisis, imatinib was administered but showed no response. BCR-ABL mutations were detected at the beginning of enrollment. The mutations were F359C, D296G, E459G, Y253H, Y253F. (2) After enrollment, patients were treated with dasatinib for 1–3months (median, 2 months). At the time of transplant, all patients achieved complete hematological response and returned to CP, and two patients achieved partial cytogenetic response. Dasatinib was well-tolerated expect one patient who developed pleural effusion. (3) Donors were HLA-haploidentical related in two cases,HLA-identical related in one case, and HLA-identical unrelated in two cases, respectively. All patients engrafted successfully, with a median time to neutrophil (>500/ul) and platelet (>30000/ul) recovery of 15 and 17 days respectively. Two patients experienced grade III-IV acute GVHD). Chronic GVHD (cGVHD) was observed in three patients, including two with extensive cGVHD. The relapse rate after transplantation was 0. Only one patient died from pulmonary fungal infection while in complete molecular remission. After a median follow-up of 6.5 months, four patients were alive with complete cytogenetic remission, including three in complete molecular remission. Conclusion: Dasatinib given before allo-HSCT do not negatively affect transplant engraftment and response rate. Myeloablative transplantation for imatinib-resistant CML may have a satisfactory outcome when combined with dasatinib, which could provide a good quality of remission prior to transplantation and a curable opportunity after transplantation. Disclosures: No relevant conflicts of interest to declare.

Imatinib Impairs the Proliferation and Function of CD4+CD25+ Regulatory T Cells in a Dose-Dependent Manner

Imatinib Impairs CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168 in Vitro

Imatinib Inhibits Both Cd4+T Regulatory Cells and Cd8+T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen Rhamm/Cd168.

Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-κB Pathway.

[Effects of Imatinib Mesylate on the Development of Dendritic Cells Derived from Bone Marrow Mononuclear Cells of Patients with Chronic Myeloid Leukemia].

Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function

Gemcitabine Treatment Enhanced the Anti-Tumor Effect of Cytokine Induced Killer Cells by Depletion of CD4+CD25bri Regulatory T Cells

Imatinib Suppresses Cryoglobulinemia and Secondary Membranoproliferative Glomerulonephritis.

Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF-β growth-suppressive signaling in BCR-ABL1-positive leukemia

IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors

Stromal Cells Attenuate the Cytotoxicity of Imatinib on Philadelphia Chromosome-Positive Leukemia Cells by Up-Regulating the VE-cadherin/β-catenin Signal

Prognostic Significance of Regulatory T-Cells and PD-1 + CD8 T-Cells in Chronic Myeloid Leukemia Patients Treated with Generic Imatinib

Imatinib Induced Molecular Response in CD34+ Hematopoietic Stem and Progenitor Cells of Patients with Chronic Myeloid Leukemia Following the First Week of Therapy

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines

Imatinib Mesilate Modifies Genes Involved in Hematopoiesis in Non Clonal Bone Marrow Cells from CML Patients in Complete Cytogenetic Response.

Imatinib (STI571) Provides Only Limited Selectivity for CML Cells and Treatment Might Be Complicated by Silent BCR-ABL Genes

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

Administration of Imatinib after Allogeneic Hematopoietic Stem Cell Transplantation May Improve Disease-Free Survival for Patients with Philadelphia Chromosome-Positive Acute Lymphobla Stic Leukemia

Prior Treatment with Dasatinib Followed by Stem Cell Transplantation in Patients with CML in Advanced Phases with BCR-ABL Mutation.

The Immunomodulatory Effect of Different FLT3 Inhibitors on Dendritic Cells

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study